Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Arizona State Retirement System

Arizona State Retirement System reduced its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 17,009 shares of the specialty pharmaceutical company’s stock after selling 242 shares during the period. Arizona State Retirement System’s holdings in Jazz Pharmaceuticals were worth $2,095,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. CIBC Asset Management Inc raised its stake in shares of Jazz Pharmaceuticals by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after acquiring an additional 97 shares during the period. UMB Bank n.a. increased its holdings in Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares during the last quarter. Jones Financial Companies Lllp raised its position in Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 130 shares during the period. Waterfront Wealth Inc. lifted its stake in Jazz Pharmaceuticals by 1.4% during the fourth quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company’s stock worth $1,191,000 after purchasing an additional 137 shares in the last quarter. Finally, Ellsworth Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 0.4% during the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock worth $4,675,000 after buying an additional 149 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ JAZZ opened at $137.45 on Tuesday. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The company has a market capitalization of $8.35 billion, a price-to-earnings ratio of 19.36, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The business has a 50-day moving average of $128.43 and a two-hundred day moving average of $120.23.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Patricia Carr sold 4,813 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the transaction, the chief accounting officer now owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 25,193 shares of company stock worth $3,533,122 over the last 90 days. 4.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JAZZ. Royal Bank of Canada cut their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. HC Wainwright increased their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $190.53.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.